Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$24.21M+30.0%-$34.57M-14.9%-$30.09M+10.7%-$33.68M-2.7%-$32.79M
$444K-11.0%$499K-12.6%$571K-12.0%$649K-5.1%$684K-3.0%
$7.11M+17.1%$6.07M+57.2%$3.86M+19.4%$3.24M+0.3%$3.23M+13.2%
-$39.11M-41.0%-$27.73M-12.5%-$24.64M+18.0%-$30.05M-1.8%-$29.52M
$93K+174%$34K-50.0%$68K-82.7%$393K+31.4%$299K-50.6%
$6.28M+106%-$103.39M-54.6%-$66.88M-16,919%-$393K-31.4%-$299K+50.6%
$39.4M
$42.36M+1,080%$3.59M-97.5%$143.76M+23,390%$612K-99.5%$127.38M+81.3%
$9.52M+107%-$127.53M-344%$52.23M+275%-$29.83M-131%$97.56M+107%
-$39.21M-41.2%-$27.76M-12.4%-$24.71M+18.8%-$30.45M-2.1%-$29.82M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Maze Therapeutics, Inc. Common Stock generate?
Maze Therapeutics, Inc. Common Stock (MAZE) generated -$121.5M in operating cash flow over the trailing twelve months.
What is Maze Therapeutics, Inc. Common Stock's free cash flow?
After $588.0K of capital expenditures, Maze Therapeutics, Inc. Common Stock's free cash flow was -$122.1M over the trailing twelve months.
Where does Maze Therapeutics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.